Compare Stocks

3 / 10
Try these comparisons:

Stock Comparison

CERT vs MEDP vs IQV

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
CERT
Certara, Inc.

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$1.03B
5Y Perf.-81.4%
MEDP
Medpace Holdings, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$12.19B
5Y Perf.+206.6%
IQV
IQVIA Holdings Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$29.95B
5Y Perf.-1.5%

CERT vs MEDP vs IQV — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
CERT logoCERT
MEDP logoMEDP
IQV logoIQV
IndustryMedical - Healthcare Information ServicesMedical - Diagnostics & ResearchMedical - Diagnostics & Research
Market Cap$1.03B$12.19B$29.95B
Revenue (TTM)$419M$2.68B$16.63B
Net Income (TTM)$-2M$460M$1.39B
Gross Margin61.5%29.1%26.1%
Operating Margin5.0%21.0%13.9%
Forward P/E14.0x25.1x13.9x
Total Debt$11M$250M$16.17B
Cash & Equiv.$189M$497M$1.98B

CERT vs MEDP vs IQVLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

CERT
MEDP
IQV
StockDec 20May 26Return
Certara, Inc. (CERT)10018.6-81.4%
Medpace Holdings, I… (MEDP)100306.6+206.6%
IQVIA Holdings Inc. (IQV)10098.5-1.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: CERT vs MEDP vs IQV

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MEDP leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Certara, Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
CERT
Certara, Inc.
The Income Pick

CERT is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • beta 1.21
  • Lower volatility, beta 1.21, Low D/E 1.1%, current ratio 2.05x
  • Beta 1.21, current ratio 2.05x
Best for: income & stability and sleep-well-at-night
MEDP
Medpace Holdings, Inc.
The Growth Play

MEDP carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 20.0%, EPS growth 21.0%, 3Y rev CAGR 20.1%
  • 14.4% 10Y total return vs IQV's 167.5%
  • 20.0% revenue growth vs IQV's 5.9%
Best for: growth exposure and long-term compounding
IQV
IQVIA Holdings Inc.
The Value Pick

IQV is the clearest fit if your priority is valuation efficiency.

  • PEG 0.34 vs MEDP's 0.79
  • Lower P/E (13.9x vs 25.1x), PEG 0.34 vs 0.79
Best for: valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthMEDP logoMEDP20.0% revenue growth vs IQV's 5.9%
ValueIQV logoIQVLower P/E (13.9x vs 25.1x), PEG 0.34 vs 0.79
Quality / MarginsMEDP logoMEDP17.2% margin vs CERT's -0.4%
Stability / SafetyCERT logoCERTBeta 1.21 vs IQV's 1.33, lower leverage
DividendsTieNone of these 3 stocks pay a meaningful dividend
Momentum (1Y)MEDP logoMEDP+47.8% vs CERT's -44.9%
Efficiency (ROA)MEDP logoMEDP24.8% ROA vs CERT's -0.1%, ROIC 154.9% vs 1.5%

CERT vs MEDP vs IQV — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

CERTCertara, Inc.
FY 2025
Reportable Segment
100.0%$419M
MEDPMedpace Holdings, Inc.
FY 2025
Oncology
29.5%$748M
Metabolic
29.4%$745M
Other
16.1%$409M
Central Nervous System
10.1%$255M
Cardiology
9.5%$239M
Antiviral And Anti Infective
5.3%$135M
IQVIQVIA Holdings Inc.
FY 2025
Research And Development Solutions
54.5%$8.9B
Technology And Analytics Solutions
40.6%$6.6B
Contract Sales And Medical Solutions
4.8%$788M

CERT vs MEDP vs IQV — Financial Metrics

Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMEDPLAGGINGIQV

Income & Cash Flow (Last 12 Months)

MEDP leads this category, winning 5 of 6 comparable metrics.

IQV is the larger business by revenue, generating $16.6B annually — 39.7x CERT's $419M. MEDP is the more profitable business, keeping 17.2% of every revenue dollar as net income compared to CERT's -0.4%. On growth, MEDP holds the edge at +26.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricCERT logoCERTCertara, Inc.MEDP logoMEDPMedpace Holdings,…IQV logoIQVIQVIA Holdings In…
RevenueTrailing 12 months$419M$2.7B$16.6B
EBITDAEarnings before interest/tax$78M$577M$3.5B
Net IncomeAfter-tax profit-$2M$460M$1.4B
Free Cash FlowCash after capex$67M$745M$2.7B
Gross MarginGross profit ÷ Revenue+61.5%+29.1%+26.1%
Operating MarginEBIT ÷ Revenue+5.0%+21.0%+13.9%
Net MarginNet income ÷ Revenue-0.4%+17.2%+8.3%
FCF MarginFCF ÷ Revenue+15.9%+27.8%+16.1%
Rev. Growth (YoY)Latest quarter vs prior year+3.3%+26.5%+8.4%
EPS Growth (YoY)Latest quarter vs prior year-191.0%+16.6%+15.0%
MEDP leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

CERT leads this category, winning 4 of 7 comparable metrics.

At 22.5x trailing earnings, IQV trades at a 19% valuation discount to MEDP's 27.9x P/E. Adjusting for growth (PEG ratio), IQV offers better value at 0.56x vs MEDP's 0.88x — a lower PEG means you pay less per unit of expected earnings growth.

MetricCERT logoCERTCertara, Inc.MEDP logoMEDPMedpace Holdings,…IQV logoIQVIQVIA Holdings In…
Market CapShares × price$1.0B$12.2B$29.9B
Enterprise ValueMkt cap + debt − cash$849M$11.9B$44.1B
Trailing P/EPrice ÷ TTM EPS-626.00x27.93x22.51x
Forward P/EPrice ÷ next-FY EPS est.13.99x25.13x13.89x
PEG RatioP/E ÷ EPS growth rate0.88x0.56x
EV / EBITDAEnterprise value multiple10.94x21.21x12.87x
Price / SalesMarket cap ÷ Revenue2.45x4.82x1.84x
Price / BookPrice ÷ Book value/share0.94x27.45x4.62x
Price / FCFMarket cap ÷ FCF10.86x17.87x14.60x
CERT leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

MEDP leads this category, winning 6 of 8 comparable metrics.

MEDP delivers a 120.9% return on equity — every $100 of shareholder capital generates $121 in annual profit, vs $-0 for CERT. CERT carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to IQV's 2.44x. On the Piotroski fundamental quality scale (0–9), CERT scores 6/9 vs IQV's 4/9, reflecting solid financial health.

MetricCERT logoCERTCertara, Inc.MEDP logoMEDPMedpace Holdings,…IQV logoIQVIQVIA Holdings In…
ROE (TTM)Return on equity-0.2%+120.9%+22.1%
ROA (TTM)Return on assets-0.1%+24.8%+4.7%
ROICReturn on invested capital+1.5%+154.9%+8.7%
ROCEReturn on capital employed+1.5%+65.7%+11.0%
Piotroski ScoreFundamental quality 0–9664
Debt / EquityFinancial leverage0.01x0.55x2.44x
Net DebtTotal debt minus cash-$178M-$247M$14.2B
Cash & Equiv.Liquid assets$189M$497M$2.0B
Total DebtShort + long-term debt$11M$250M$16.2B
Interest CoverageEBIT ÷ Interest expense3.10x
MEDP leads this category, winning 6 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

MEDP leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in MEDP five years ago would be worth $26,038 today (with dividends reinvested), compared to $2,131 for CERT. Over the past 12 months, MEDP leads with a +47.8% total return vs CERT's -44.9%. The 3-year compound annual growth rate (CAGR) favors MEDP at 26.8% vs CERT's -35.6% — a key indicator of consistent wealth creation.

MetricCERT logoCERTCertara, Inc.MEDP logoMEDPMedpace Holdings,…IQV logoIQVIQVIA Holdings In…
YTD ReturnYear-to-date-28.4%-25.3%-21.7%
1-Year ReturnPast 12 months-44.9%+47.8%+20.7%
3-Year ReturnCumulative with dividends-73.3%+103.7%-7.0%
5-Year ReturnCumulative with dividends-78.7%+160.4%-23.7%
10-Year ReturnCumulative with dividends-83.6%+1435.8%+167.5%
CAGR (3Y)Annualised 3-year return-35.6%+26.8%-2.4%
MEDP leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — CERT and IQV each lead in 1 of 2 comparable metrics.

CERT is the less volatile stock with a 1.21 beta — it tends to amplify market swings less than IQV's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IQV currently trades 71.4% from its 52-week high vs CERT's 45.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCERT logoCERTCertara, Inc.MEDP logoMEDPMedpace Holdings,…IQV logoIQVIQVIA Holdings In…
Beta (5Y)Sensitivity to S&P 5001.21x1.26x1.33x
52-Week HighHighest price in past year$13.88$628.92$247.05
52-Week LowLowest price in past year$5.19$284.10$134.65
% of 52W HighCurrent price vs 52-week peak+45.1%+67.9%+71.4%
RSI (14)Momentum oscillator 0–10051.341.558.4
Avg Volume (50D)Average daily shares traded3.6M372K1.6M
Evenly matched — CERT and IQV each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: CERT as "Buy", MEDP as "Hold", IQV as "Buy". Consensus price targets imply 59.7% upside for CERT (target: $10) vs 16.9% for MEDP (target: $499).

MetricCERT logoCERTCertara, Inc.MEDP logoMEDPMedpace Holdings,…IQV logoIQVIQVIA Holdings In…
Analyst RatingConsensus buy/hold/sellBuyHoldBuy
Price TargetConsensus 12-month target$10.00$498.86$225.63
# AnalystsCovering analysts141944
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises2
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+4.2%+7.5%+4.2%
Insufficient data to determine a leader in this category.
Key Takeaway

MEDP leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CERT leads in 1 (Valuation Metrics). 1 tied.

Best OverallMedpace Holdings, Inc. (MEDP)Leads 3 of 6 categories
Loading custom metrics...

CERT vs MEDP vs IQV: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is CERT or MEDP or IQV a better buy right now?

For growth investors, Medpace Holdings, Inc.

(MEDP) is the stronger pick with 20. 0% revenue growth year-over-year, versus 5. 9% for IQVIA Holdings Inc. (IQV). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 5x trailing P/E (13. 9x forward), making it the more compelling value choice. Analysts rate Certara, Inc. (CERT) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — CERT or MEDP or IQV?

On trailing P/E, IQVIA Holdings Inc.

(IQV) is the cheapest at 22. 5x versus Medpace Holdings, Inc. at 27. 9x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 13. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 34x versus Medpace Holdings, Inc. 's 0. 79x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — CERT or MEDP or IQV?

Over the past 5 years, Medpace Holdings, Inc.

(MEDP) delivered a total return of +160. 4%, compared to -78. 7% for Certara, Inc. (CERT). Over 10 years, the gap is even starker: MEDP returned +1436% versus CERT's -83. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — CERT or MEDP or IQV?

By beta (market sensitivity over 5 years), Certara, Inc.

(CERT) is the lower-risk stock at 1. 21β versus IQVIA Holdings Inc. 's 1. 33β — meaning IQV is approximately 10% more volatile than CERT relative to the S&P 500. On balance sheet safety, Certara, Inc. (CERT) carries a lower debt/equity ratio of 1% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — CERT or MEDP or IQV?

By revenue growth (latest reported year), Medpace Holdings, Inc.

(MEDP) is pulling ahead at 20. 0% versus 5. 9% for IQVIA Holdings Inc. (IQV). On earnings-per-share growth, the picture is similar: Certara, Inc. grew EPS 86. 7% year-over-year, compared to 4. 7% for IQVIA Holdings Inc.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — CERT or MEDP or IQV?

Medpace Holdings, Inc.

(MEDP) is the more profitable company, earning 17. 8% net margin versus -0. 4% for Certara, Inc. — meaning it keeps 17. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MEDP leads at 21. 1% versus 5. 0% for CERT. At the gross margin level — before operating expenses — CERT leads at 61. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is CERT or MEDP or IQV more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 34x versus Medpace Holdings, Inc. 's 0. 79x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, IQVIA Holdings Inc. (IQV) trades at 13. 9x forward P/E versus 25. 1x for Medpace Holdings, Inc. — 11. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CERT: 59. 7% to $10. 00.

08

Which pays a better dividend — CERT or MEDP or IQV?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is CERT or MEDP or IQV better for a retirement portfolio?

For long-horizon retirement investors, Medpace Holdings, Inc.

(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26), +1436% 10Y return). Both have compounded well over 10 years (MEDP: +1436%, CERT: -83. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between CERT and MEDP and IQV?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CERT is a small-cap quality compounder stock; MEDP is a mid-cap high-growth stock; IQV is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

CERT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 36%
Run This Screen
Stocks Like

MEDP

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 13%
  • Net Margin > 10%
Run This Screen
Stocks Like

IQV

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform CERT and MEDP and IQV on the metrics below

Revenue Growth>
%
(CERT: 3.3% · MEDP: 26.5%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.